News Summary

R3 Bio, a biotech startup based in the Bay Area, is pioneering an innovative solution to replace animal testing with ‘organ sacks.’ Backed by the Singapore-based longevity fund Immortal Dragons, the startup aims to create nonsentient organ structures that lack a brain, thus avoiding ethical concerns associated with animal testing. The company’s long-term vision is to develop human organ sacks for tissue and organ sourcing. Currently, R3 Bio is focusing on developing monkey organ sacks, which could provide a scalable and ethical alternative to animal testing. This approach aligns with the broader trend of reducing reliance on animal testing across federal agencies in the US. The concept of organ sacks could revolutionize drug testing, offering a viable substitute to traditional organ-on-chip models by incorporating the complex structures of full organs.